- Home
- ACRS vs BFST Comparison
ACRS vs BFST Comparison
Compare ACRS & BFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRS | BFST |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 1.0B |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ACRS | BFST |
|---|---|---|
| Price | $5.52 | $30.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $10.20 | ★ $32.75 |
| AVG Volume (30 Days) | ★ 2.4M | 161.4K |
| Earning Date | 05-07-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 2.23% |
| EPS Growth | ★ 69.01 | 23.45 |
| EPS | N/A | ★ 1.37 |
| Revenue | $1,683,000.00 | ★ $10,704,000.00 |
| Revenue This Year | N/A | $22.71 |
| Revenue Next Year | $4.24 | $5.02 |
| P/E Ratio | ★ N/A | $22.50 |
| Revenue Growth | N/A | ★ 1.20 |
| 52 Week Low | $1.74 | $22.56 |
| 52 Week High | $6.60 | $32.53 |
Technical Indicators
Market Signals| Indicator | ACRS | BFST |
|---|---|---|
| Relative Strength Index (RSI) | 43.76 | 38.68 |
| Support Level | $4.13 | $29.48 |
| Resistance Level | $5.87 | $31.63 |
| Average True Range (ATR) | 0.33 | 0.49 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 40.93 | 4.26 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.